Five9 FIVN 深 沪
等待开盘 12-18 09:30:00 美东时间
21.11
-0.400
-1.86%
华盛通- 最 高22.08
- 今 开21.275
- 成交量 141.32万股
- 最 低 21.041
- 昨 收 21.51
- 总市值 16.31亿
- 52周最高 49.90
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 17.71
- 委 比 -50.16%
- 总股本 7726.27万
- 历史最高 211.68
- 量 比 0.89
- 振 幅 4.83%
- 历史最低 3.48
- 每 手 1
- 风险率 6.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Five9 appoints Amit Mathradas as next CEO
Five9 (FIVN) on Wednesday appointed Amit Mathradas as the CEO and Director, effective February 2, 2026. Mike Burkland, current board chairman, is to retire from the CEO position in July, and Mathrada...
12-17 23:59
Five9 Appoints Amit Mathrada CEO, Effective Feb. 2, Succeeding Mike Burkland
Five9, Inc. (NASDAQ: FIVN) ("Five9" or the "Company"), provider of the Intelligent CX Platform, today announced that its Board of Directors (the "Board") has appointed Amit Mathradas as the Company's Chief Executive
12-17 21:31
A Seismic Shift in Tech Value Scores: The Four Stocks to Watch
The tech sector's value scores are experiencing a seismic shift, with four stocks leading the pack in significant gains.
11-13 04:23
Five9 launches $50M accelerated share repurchase
Five9 (FIVN) said on Tuesday it has begun a $50 million accelerated share repurchase ("ASR") agreement with JPMorgan Chase Bank to buy back its common stock. Under the ASR, Five9 will make an initial ...
11-12 05:13
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Five9 Analysts Slash Their Forecasts After Q3 Earnings
Five9 (NASDAQ:FIVN) reported better-than-expected earnings for the third quarte...
11-08 03:24
Piper Sandler Maintains Overweight on Five9, Lowers Price Target to $26
Piper Sandler analyst James Fish maintains Five9 (NASDAQ:FIVN) with a Overweight and lowers the price target from $31 to $26.
11-07 20:41
Five9 Q3 Adj. EPS $0.78 Beats $0.73 Estimate, Sales $285.800M Beat $285.042M Estimate
Five9 (NASDAQ:FIVN) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.73 by 6.56 percent. This is a 16.42 percent increase over earnings of $0.67 per share from the same
11-07 05:09
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
